LQDA logo

LQDALiquidia Corp

$72.94
$1.14
(1.59%)
Pre-Market
Updated: 05:22 AM EDT·Prev Close $71.80
EarningsAug 12
Mkt Cap$6.33B
Vol2,748.00
News
all
press releases
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Zacks
News Placeholder
More News
News Placeholder
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Zacks
News Placeholder
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.
Zacks
News Placeholder
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
Zacks
News Placeholder
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
Zacks
News Placeholder
INDV Stock: What Sublocade Growth Signals for 2026
Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.
Zacks
News Placeholder
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Zacks
News Placeholder
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.
Zacks
News Placeholder
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Zacks
News Placeholder
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.
Zacks
<
1
2
...
>

Advertisement|Remove ads.